Literature DB >> 1445318

Selective endothelial growth inhibition by tetracyclines that inhibit collagenase.

C Guerin1, J Laterra, T Masnyk, L M Golub, H Brem.   

Abstract

The potential of angiogenesis inhibitors as therapy for human diseases is limited by a lack of clinically available agents. We investigated the mechanism of the anti-angiogenesis effects of minocycline, a commonly used drug, and several derivatives. Endothelial cell proliferation was inhibited by several of these compounds. We found that inhibition was associated with inhibition of collagenase, did not require antibiotic activity, and was not related to cytotoxicity. Other microvessel-associated cells were unaffected. This endothelial antiproliferative effect is a potential mechanism of the anti-angiogenic activity of minocycline.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445318     DOI: 10.1016/0006-291x(92)91118-a

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Local anti-angiogenic brain tumor therapies.

Authors:  E P Sipos; H Brem
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

2.  Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells.

Authors:  Katrina L Mealey; Rola Barhoumi; Robert C Burghardt; Stephen Safe; Deborah T Kochevar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.

Authors:  Christopher Franco; Bernard Ho; Diane Mulholland; Guangpei Hou; Muzharul Islam; Katey Donaldson; Michelle Patricia Bendeck
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

4.  The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism.

Authors:  S Gilbertson-Beadling; E A Powers; M Stamp-Cole; P S Scott; T L Wallace; J Copeland; G Petzold; M Mitchell; S Ledbetter; R Poorman
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

6.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

7.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.

Authors:  Muzharul M Islam; Christopher D Franco; David W Courtman; Michelle P Bendeck
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

8.  Detection of biological activity in the cerebrospinal fluid of patients with central nervous system tumors.

Authors:  D Tapper; M A Cahan; H Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.

Authors:  Christopher Guerin; Alessandro Olivi; Jon D Weingart; H Christopher Lawson; Henry Brem
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

10.  H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption.

Authors:  K Ohishi; N Fujita; Y Morinaga; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.